COVID-19 Impact on Global Live Attenuated Vaccine, Market Insights and Forecast to 2026
Live Attenuated Vaccine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Live Attenuated Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Live Attenuated Vaccine market is segmented into
The Live Attenuated Vaccine market is analysed and market size information is provided by regions (countries).
The key regions covered in the Live Attenuated Vaccine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Live Attenuated Vaccine Market Share Analysis
Live Attenuated Vaccine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Live Attenuated Vaccine business, the date to enter into the Live Attenuated Vaccine market, Live Attenuated Vaccine product introduction, recent developments, etc.
The major vendors covered:
Segment by Type, the Live Attenuated Vaccine market is segmented into
- Children
- Adult
- Hospital
- Medical Center
- Others
The Live Attenuated Vaccine market is analysed and market size information is provided by regions (countries).
The key regions covered in the Live Attenuated Vaccine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Live Attenuated Vaccine Market Share Analysis
Live Attenuated Vaccine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Live Attenuated Vaccine business, the date to enter into the Live Attenuated Vaccine market, Live Attenuated Vaccine product introduction, recent developments, etc.
The major vendors covered:
- Astellas Pharma (Japan)
- CSL Limited (Australia)
- Emergent BioSolutions (U.S.)
- GlaxoSmithKline (U.K.)
- Johnson & Johnson (U.S.)
- MedImmune (U.S.)
- Merck & Co (U.S.)
- Pfizer (U.S.)
- Sanofi Pasteur (France)
- Serum Institute of India Pvt (India)
1 STUDY COVERAGE
1.1 Live Attenuated Vaccine Product Introduction
1.2 Market Segments
1.3 Key Live Attenuated Vaccine Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Live Attenuated Vaccine Market Size Growth Rate by Type
1.4.2 Children
1.4.3 Adult
1.5 Market by Application
1.5.1 Global Live Attenuated Vaccine Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Medical Center
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Live Attenuated Vaccine Industry Impact
1.6.1 How the Covid-19 is Affecting the Live Attenuated Vaccine Industry
1.6.1.1 Live Attenuated Vaccine Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Live Attenuated Vaccine Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Live Attenuated Vaccine Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Live Attenuated Vaccine Market Size Estimates and Forecasts
2.1.1 Global Live Attenuated Vaccine Revenue 2015-2026
2.1.2 Global Live Attenuated Vaccine Sales 2015-2026
2.2 Live Attenuated Vaccine Market Size by Region: 2020 Versus 2026
2.2.1 Global Live Attenuated Vaccine Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Live Attenuated Vaccine Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL LIVE ATTENUATED VACCINE COMPETITOR LANDSCAPE BY PLAYERS
3.1 Live Attenuated Vaccine Sales by Manufacturers
3.1.1 Live Attenuated Vaccine Sales by Manufacturers (2015-2020)
3.1.2 Live Attenuated Vaccine Sales Market Share by Manufacturers (2015-2020)
3.2 Live Attenuated Vaccine Revenue by Manufacturers
3.2.1 Live Attenuated Vaccine Revenue by Manufacturers (2015-2020)
3.2.2 Live Attenuated Vaccine Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Live Attenuated Vaccine Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Live Attenuated Vaccine Revenue in 2019
3.2.5 Global Live Attenuated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Live Attenuated Vaccine Price by Manufacturers
3.4 Live Attenuated Vaccine Manufacturing Base Distribution, Product Types
3.4.1 Live Attenuated Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Live Attenuated Vaccine Product Type
3.4.3 Date of International Manufacturers Enter into Live Attenuated Vaccine Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Live Attenuated Vaccine Market Size by Type (2015-2020)
4.1.1 Global Live Attenuated Vaccine Sales by Type (2015-2020)
4.1.2 Global Live Attenuated Vaccine Revenue by Type (2015-2020)
4.1.3 Live Attenuated Vaccine Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Live Attenuated Vaccine Market Size Forecast by Type (2021-2026)
4.2.1 Global Live Attenuated Vaccine Sales Forecast by Type (2021-2026)
4.2.2 Global Live Attenuated Vaccine Revenue Forecast by Type (2021-2026)
4.2.3 Live Attenuated Vaccine Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Live Attenuated Vaccine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Live Attenuated Vaccine Market Size by Application (2015-2020)
5.1.1 Global Live Attenuated Vaccine Sales by Application (2015-2020)
5.1.2 Global Live Attenuated Vaccine Revenue by Application (2015-2020)
5.1.3 Live Attenuated Vaccine Price by Application (2015-2020)
5.2 Live Attenuated Vaccine Market Size Forecast by Application (2021-2026)
5.2.1 Global Live Attenuated Vaccine Sales Forecast by Application (2021-2026)
5.2.2 Global Live Attenuated Vaccine Revenue Forecast by Application (2021-2026)
5.2.3 Global Live Attenuated Vaccine Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Live Attenuated Vaccine by Country
6.1.1 North America Live Attenuated Vaccine Sales by Country
6.1.2 North America Live Attenuated Vaccine Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Live Attenuated Vaccine Market Facts & Figures by Type
6.3 North America Live Attenuated Vaccine Market Facts & Figures by Application
7 EUROPE
7.1 Europe Live Attenuated Vaccine by Country
7.1.1 Europe Live Attenuated Vaccine Sales by Country
7.1.2 Europe Live Attenuated Vaccine Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Live Attenuated Vaccine Market Facts & Figures by Type
7.3 Europe Live Attenuated Vaccine Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Live Attenuated Vaccine by Region
8.1.1 Asia Pacific Live Attenuated Vaccine Sales by Region
8.1.2 Asia Pacific Live Attenuated Vaccine Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Live Attenuated Vaccine Market Facts & Figures by Type
8.3 Asia Pacific Live Attenuated Vaccine Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Live Attenuated Vaccine by Country
9.1.1 Latin America Live Attenuated Vaccine Sales by Country
9.1.2 Latin America Live Attenuated Vaccine Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Live Attenuated Vaccine Market Facts & Figures by Type
9.3 Central & South America Live Attenuated Vaccine Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Live Attenuated Vaccine by Country
10.1.1 Middle East and Africa Live Attenuated Vaccine Sales by Country
10.1.2 Middle East and Africa Live Attenuated Vaccine Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Live Attenuated Vaccine Market Facts & Figures by Type
10.3 Middle East and Africa Live Attenuated Vaccine Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Astellas Pharma (Japan)
11.1.1 Astellas Pharma (Japan) Corporation Information
11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue
11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma (Japan) Live Attenuated Vaccine Products Offered
11.1.5 Astellas Pharma (Japan) Recent Development
11.2 CSL Limited (Australia)
11.2.1 CSL Limited (Australia) Corporation Information
11.2.2 CSL Limited (Australia) Description, Business Overview and Total Revenue
11.2.3 CSL Limited (Australia) Sales, Revenue and Gross Margin (2015-2020)
11.2.4 CSL Limited (Australia) Live Attenuated Vaccine Products Offered
11.2.5 CSL Limited (Australia) Recent Development
11.3 Emergent BioSolutions (U.S.)
11.3.1 Emergent BioSolutions (U.S.) Corporation Information
11.3.2 Emergent BioSolutions (U.S.) Description, Business Overview and Total Revenue
11.3.3 Emergent BioSolutions (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Emergent BioSolutions (U.S.) Live Attenuated Vaccine Products Offered
11.3.5 Emergent BioSolutions (U.S.) Recent Development
11.4 GlaxoSmithKline (U.K.)
11.4.1 GlaxoSmithKline (U.K.) Corporation Information
11.4.2 GlaxoSmithKline (U.K.) Description, Business Overview and Total Revenue
11.4.3 GlaxoSmithKline (U.K.) Sales, Revenue and Gross Margin (2015-2020)
11.4.4 GlaxoSmithKline (U.K.) Live Attenuated Vaccine Products Offered
11.4.5 GlaxoSmithKline (U.K.) Recent Development
11.5 Johnson & Johnson (U.S.)
11.5.1 Johnson & Johnson (U.S.) Corporation Information
11.5.2 Johnson & Johnson (U.S.) Description, Business Overview and Total Revenue
11.5.3 Johnson & Johnson (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Johnson & Johnson (U.S.) Live Attenuated Vaccine Products Offered
11.5.5 Johnson & Johnson (U.S.) Recent Development
11.6 MedImmune (U.S.)
11.6.1 MedImmune (U.S.) Corporation Information
11.6.2 MedImmune (U.S.) Description, Business Overview and Total Revenue
11.6.3 MedImmune (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.6.4 MedImmune (U.S.) Live Attenuated Vaccine Products Offered
11.6.5 MedImmune (U.S.) Recent Development
11.7 Merck & Co (U.S.)
11.7.1 Merck & Co (U.S.) Corporation Information
11.7.2 Merck & Co (U.S.) Description, Business Overview and Total Revenue
11.7.3 Merck & Co (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Merck & Co (U.S.) Live Attenuated Vaccine Products Offered
11.7.5 Merck & Co (U.S.) Recent Development
11.8 Pfizer (U.S.)
11.8.1 Pfizer (U.S.) Corporation Information
11.8.2 Pfizer (U.S.) Description, Business Overview and Total Revenue
11.8.3 Pfizer (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Pfizer (U.S.) Live Attenuated Vaccine Products Offered
11.8.5 Pfizer (U.S.) Recent Development
11.9 Sanofi Pasteur (France)
11.9.1 Sanofi Pasteur (France) Corporation Information
11.9.2 Sanofi Pasteur (France) Description, Business Overview and Total Revenue
11.9.3 Sanofi Pasteur (France) Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Sanofi Pasteur (France) Live Attenuated Vaccine Products Offered
11.9.5 Sanofi Pasteur (France) Recent Development
11.10 Serum Institute of India Pvt (India)
11.10.1 Serum Institute of India Pvt (India) Corporation Information
11.10.2 Serum Institute of India Pvt (India) Description, Business Overview and Total Revenue
11.10.3 Serum Institute of India Pvt (India) Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Serum Institute of India Pvt (India) Live Attenuated Vaccine Products Offered
11.10.5 Serum Institute of India Pvt (India) Recent Development
11.1 Astellas Pharma (Japan)
11.1.1 Astellas Pharma (Japan) Corporation Information
11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue
11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma (Japan) Live Attenuated Vaccine Products Offered
11.1.5 Astellas Pharma (Japan) Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Live Attenuated Vaccine Market Estimates and Projections by Region
12.1.1 Global Live Attenuated Vaccine Sales Forecast by Regions 2021-2026
12.1.2 Global Live Attenuated Vaccine Revenue Forecast by Regions 2021-2026
12.2 North America Live Attenuated Vaccine Market Size Forecast (2021-2026)
12.2.1 North America: Live Attenuated Vaccine Sales Forecast (2021-2026)
12.2.2 North America: Live Attenuated Vaccine Revenue Forecast (2021-2026)
12.2.3 North America: Live Attenuated Vaccine Market Size Forecast by Country (2021-2026)
12.3 Europe Live Attenuated Vaccine Market Size Forecast (2021-2026)
12.3.1 Europe: Live Attenuated Vaccine Sales Forecast (2021-2026)
12.3.2 Europe: Live Attenuated Vaccine Revenue Forecast (2021-2026)
12.3.3 Europe: Live Attenuated Vaccine Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Live Attenuated Vaccine Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Live Attenuated Vaccine Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Live Attenuated Vaccine Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Live Attenuated Vaccine Market Size Forecast by Region (2021-2026)
12.5 Latin America Live Attenuated Vaccine Market Size Forecast (2021-2026)
12.5.1 Latin America: Live Attenuated Vaccine Sales Forecast (2021-2026)
12.5.2 Latin America: Live Attenuated Vaccine Revenue Forecast (2021-2026)
12.5.3 Latin America: Live Attenuated Vaccine Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Live Attenuated Vaccine Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Live Attenuated Vaccine Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Live Attenuated Vaccine Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Live Attenuated Vaccine Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Live Attenuated Vaccine Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Live Attenuated Vaccine Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
1.1 Live Attenuated Vaccine Product Introduction
1.2 Market Segments
1.3 Key Live Attenuated Vaccine Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Live Attenuated Vaccine Market Size Growth Rate by Type
1.4.2 Children
1.4.3 Adult
1.5 Market by Application
1.5.1 Global Live Attenuated Vaccine Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Medical Center
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Live Attenuated Vaccine Industry Impact
1.6.1 How the Covid-19 is Affecting the Live Attenuated Vaccine Industry
1.6.1.1 Live Attenuated Vaccine Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Live Attenuated Vaccine Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Live Attenuated Vaccine Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Live Attenuated Vaccine Market Size Estimates and Forecasts
2.1.1 Global Live Attenuated Vaccine Revenue 2015-2026
2.1.2 Global Live Attenuated Vaccine Sales 2015-2026
2.2 Live Attenuated Vaccine Market Size by Region: 2020 Versus 2026
2.2.1 Global Live Attenuated Vaccine Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Live Attenuated Vaccine Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL LIVE ATTENUATED VACCINE COMPETITOR LANDSCAPE BY PLAYERS
3.1 Live Attenuated Vaccine Sales by Manufacturers
3.1.1 Live Attenuated Vaccine Sales by Manufacturers (2015-2020)
3.1.2 Live Attenuated Vaccine Sales Market Share by Manufacturers (2015-2020)
3.2 Live Attenuated Vaccine Revenue by Manufacturers
3.2.1 Live Attenuated Vaccine Revenue by Manufacturers (2015-2020)
3.2.2 Live Attenuated Vaccine Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Live Attenuated Vaccine Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Live Attenuated Vaccine Revenue in 2019
3.2.5 Global Live Attenuated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Live Attenuated Vaccine Price by Manufacturers
3.4 Live Attenuated Vaccine Manufacturing Base Distribution, Product Types
3.4.1 Live Attenuated Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Live Attenuated Vaccine Product Type
3.4.3 Date of International Manufacturers Enter into Live Attenuated Vaccine Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Live Attenuated Vaccine Market Size by Type (2015-2020)
4.1.1 Global Live Attenuated Vaccine Sales by Type (2015-2020)
4.1.2 Global Live Attenuated Vaccine Revenue by Type (2015-2020)
4.1.3 Live Attenuated Vaccine Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Live Attenuated Vaccine Market Size Forecast by Type (2021-2026)
4.2.1 Global Live Attenuated Vaccine Sales Forecast by Type (2021-2026)
4.2.2 Global Live Attenuated Vaccine Revenue Forecast by Type (2021-2026)
4.2.3 Live Attenuated Vaccine Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Live Attenuated Vaccine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Live Attenuated Vaccine Market Size by Application (2015-2020)
5.1.1 Global Live Attenuated Vaccine Sales by Application (2015-2020)
5.1.2 Global Live Attenuated Vaccine Revenue by Application (2015-2020)
5.1.3 Live Attenuated Vaccine Price by Application (2015-2020)
5.2 Live Attenuated Vaccine Market Size Forecast by Application (2021-2026)
5.2.1 Global Live Attenuated Vaccine Sales Forecast by Application (2021-2026)
5.2.2 Global Live Attenuated Vaccine Revenue Forecast by Application (2021-2026)
5.2.3 Global Live Attenuated Vaccine Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Live Attenuated Vaccine by Country
6.1.1 North America Live Attenuated Vaccine Sales by Country
6.1.2 North America Live Attenuated Vaccine Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Live Attenuated Vaccine Market Facts & Figures by Type
6.3 North America Live Attenuated Vaccine Market Facts & Figures by Application
7 EUROPE
7.1 Europe Live Attenuated Vaccine by Country
7.1.1 Europe Live Attenuated Vaccine Sales by Country
7.1.2 Europe Live Attenuated Vaccine Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Live Attenuated Vaccine Market Facts & Figures by Type
7.3 Europe Live Attenuated Vaccine Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Live Attenuated Vaccine by Region
8.1.1 Asia Pacific Live Attenuated Vaccine Sales by Region
8.1.2 Asia Pacific Live Attenuated Vaccine Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Live Attenuated Vaccine Market Facts & Figures by Type
8.3 Asia Pacific Live Attenuated Vaccine Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Live Attenuated Vaccine by Country
9.1.1 Latin America Live Attenuated Vaccine Sales by Country
9.1.2 Latin America Live Attenuated Vaccine Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Live Attenuated Vaccine Market Facts & Figures by Type
9.3 Central & South America Live Attenuated Vaccine Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Live Attenuated Vaccine by Country
10.1.1 Middle East and Africa Live Attenuated Vaccine Sales by Country
10.1.2 Middle East and Africa Live Attenuated Vaccine Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Live Attenuated Vaccine Market Facts & Figures by Type
10.3 Middle East and Africa Live Attenuated Vaccine Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Astellas Pharma (Japan)
11.1.1 Astellas Pharma (Japan) Corporation Information
11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue
11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma (Japan) Live Attenuated Vaccine Products Offered
11.1.5 Astellas Pharma (Japan) Recent Development
11.2 CSL Limited (Australia)
11.2.1 CSL Limited (Australia) Corporation Information
11.2.2 CSL Limited (Australia) Description, Business Overview and Total Revenue
11.2.3 CSL Limited (Australia) Sales, Revenue and Gross Margin (2015-2020)
11.2.4 CSL Limited (Australia) Live Attenuated Vaccine Products Offered
11.2.5 CSL Limited (Australia) Recent Development
11.3 Emergent BioSolutions (U.S.)
11.3.1 Emergent BioSolutions (U.S.) Corporation Information
11.3.2 Emergent BioSolutions (U.S.) Description, Business Overview and Total Revenue
11.3.3 Emergent BioSolutions (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Emergent BioSolutions (U.S.) Live Attenuated Vaccine Products Offered
11.3.5 Emergent BioSolutions (U.S.) Recent Development
11.4 GlaxoSmithKline (U.K.)
11.4.1 GlaxoSmithKline (U.K.) Corporation Information
11.4.2 GlaxoSmithKline (U.K.) Description, Business Overview and Total Revenue
11.4.3 GlaxoSmithKline (U.K.) Sales, Revenue and Gross Margin (2015-2020)
11.4.4 GlaxoSmithKline (U.K.) Live Attenuated Vaccine Products Offered
11.4.5 GlaxoSmithKline (U.K.) Recent Development
11.5 Johnson & Johnson (U.S.)
11.5.1 Johnson & Johnson (U.S.) Corporation Information
11.5.2 Johnson & Johnson (U.S.) Description, Business Overview and Total Revenue
11.5.3 Johnson & Johnson (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Johnson & Johnson (U.S.) Live Attenuated Vaccine Products Offered
11.5.5 Johnson & Johnson (U.S.) Recent Development
11.6 MedImmune (U.S.)
11.6.1 MedImmune (U.S.) Corporation Information
11.6.2 MedImmune (U.S.) Description, Business Overview and Total Revenue
11.6.3 MedImmune (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.6.4 MedImmune (U.S.) Live Attenuated Vaccine Products Offered
11.6.5 MedImmune (U.S.) Recent Development
11.7 Merck & Co (U.S.)
11.7.1 Merck & Co (U.S.) Corporation Information
11.7.2 Merck & Co (U.S.) Description, Business Overview and Total Revenue
11.7.3 Merck & Co (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Merck & Co (U.S.) Live Attenuated Vaccine Products Offered
11.7.5 Merck & Co (U.S.) Recent Development
11.8 Pfizer (U.S.)
11.8.1 Pfizer (U.S.) Corporation Information
11.8.2 Pfizer (U.S.) Description, Business Overview and Total Revenue
11.8.3 Pfizer (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Pfizer (U.S.) Live Attenuated Vaccine Products Offered
11.8.5 Pfizer (U.S.) Recent Development
11.9 Sanofi Pasteur (France)
11.9.1 Sanofi Pasteur (France) Corporation Information
11.9.2 Sanofi Pasteur (France) Description, Business Overview and Total Revenue
11.9.3 Sanofi Pasteur (France) Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Sanofi Pasteur (France) Live Attenuated Vaccine Products Offered
11.9.5 Sanofi Pasteur (France) Recent Development
11.10 Serum Institute of India Pvt (India)
11.10.1 Serum Institute of India Pvt (India) Corporation Information
11.10.2 Serum Institute of India Pvt (India) Description, Business Overview and Total Revenue
11.10.3 Serum Institute of India Pvt (India) Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Serum Institute of India Pvt (India) Live Attenuated Vaccine Products Offered
11.10.5 Serum Institute of India Pvt (India) Recent Development
11.1 Astellas Pharma (Japan)
11.1.1 Astellas Pharma (Japan) Corporation Information
11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue
11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma (Japan) Live Attenuated Vaccine Products Offered
11.1.5 Astellas Pharma (Japan) Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Live Attenuated Vaccine Market Estimates and Projections by Region
12.1.1 Global Live Attenuated Vaccine Sales Forecast by Regions 2021-2026
12.1.2 Global Live Attenuated Vaccine Revenue Forecast by Regions 2021-2026
12.2 North America Live Attenuated Vaccine Market Size Forecast (2021-2026)
12.2.1 North America: Live Attenuated Vaccine Sales Forecast (2021-2026)
12.2.2 North America: Live Attenuated Vaccine Revenue Forecast (2021-2026)
12.2.3 North America: Live Attenuated Vaccine Market Size Forecast by Country (2021-2026)
12.3 Europe Live Attenuated Vaccine Market Size Forecast (2021-2026)
12.3.1 Europe: Live Attenuated Vaccine Sales Forecast (2021-2026)
12.3.2 Europe: Live Attenuated Vaccine Revenue Forecast (2021-2026)
12.3.3 Europe: Live Attenuated Vaccine Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Live Attenuated Vaccine Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Live Attenuated Vaccine Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Live Attenuated Vaccine Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Live Attenuated Vaccine Market Size Forecast by Region (2021-2026)
12.5 Latin America Live Attenuated Vaccine Market Size Forecast (2021-2026)
12.5.1 Latin America: Live Attenuated Vaccine Sales Forecast (2021-2026)
12.5.2 Latin America: Live Attenuated Vaccine Revenue Forecast (2021-2026)
12.5.3 Latin America: Live Attenuated Vaccine Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Live Attenuated Vaccine Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Live Attenuated Vaccine Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Live Attenuated Vaccine Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Live Attenuated Vaccine Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Live Attenuated Vaccine Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Live Attenuated Vaccine Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
LIST OF TABLES
Table 1. Live Attenuated Vaccine Market Segments
Table 2. Ranking of Global Top Live Attenuated Vaccine Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Live Attenuated Vaccine Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Children
Table 5. Major Manufacturers of Adult
Table 6. COVID-19 Impact Global Market: (Four Live Attenuated Vaccine Market Size Forecast Scenarios)
Table 7. Opportunities and Trends for Live Attenuated Vaccine Players in the COVID-19 Landscape
Table 8. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 9. Key Regions/Countries Measures against Covid-19 Impact
Table 10. Proposal for Live Attenuated Vaccine Players to Combat Covid-19 Impact
Table 11. Global Live Attenuated Vaccine Market Size Growth Rate by Application 2020-2026 (K MT)
Table 12. Global Live Attenuated Vaccine Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 13. Global Live Attenuated Vaccine Sales by Regions 2015-2020 (K MT)
Table 14. Global Live Attenuated Vaccine Sales Market Share by Regions (2015-2020)
Table 15. Global Live Attenuated Vaccine Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Live Attenuated Vaccine Sales by Manufacturers (2015-2020) (K MT)
Table 17. Global Live Attenuated Vaccine Sales Share by Manufacturers (2015-2020)
Table 18. Global Live Attenuated Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Live Attenuated Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Live Attenuated Vaccine as of 2019)
Table 20. Live Attenuated Vaccine Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Live Attenuated Vaccine Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Live Attenuated Vaccine Price (2015-2020) (USD/MT)
Table 23. Live Attenuated Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Live Attenuated Vaccine Product Type
Table 25. Date of International Manufacturers Enter into Live Attenuated Vaccine Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 28. Global Live Attenuated Vaccine Sales Share by Type (2015-2020)
Table 29. Global Live Attenuated Vaccine Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Live Attenuated Vaccine Revenue Share by Type (2015-2020)
Table 31. Live Attenuated Vaccine Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 32. Global Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 33. Global Live Attenuated Vaccine Sales Share by Application (2015-2020)
Table 34. North America Live Attenuated Vaccine Sales by Country (2015-2020) (K MT)
Table 35. North America Live Attenuated Vaccine Sales Market Share by Country (2015-2020)
Table 36. North America Live Attenuated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 37. North America Live Attenuated Vaccine Revenue Market Share by Country (2015-2020)
Table 38. North America Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 39. North America Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Table 40. North America Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 41. North America Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Table 42. Europe Live Attenuated Vaccine Sales by Country (2015-2020) (K MT)
Table 43. Europe Live Attenuated Vaccine Sales Market Share by Country (2015-2020)
Table 44. Europe Live Attenuated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe Live Attenuated Vaccine Revenue Market Share by Country (2015-2020)
Table 46. Europe Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 47. Europe Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Table 48. Europe Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 49. Europe Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific Live Attenuated Vaccine Sales by Region (2015-2020) (K MT)
Table 51. Asia Pacific Live Attenuated Vaccine Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific Live Attenuated Vaccine Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific Live Attenuated Vaccine Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 55. Asia Pacific Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 57. Asia Pacific Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Table 58. Latin America Live Attenuated Vaccine Sales by Country (2015-2020) (K MT)
Table 59. Latin America Live Attenuated Vaccine Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa Live Attenuated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America Live Attenuated Vaccine Revenue Market Share by Country (2015-2020)
Table 62. Latin America Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 63. Latin America Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Table 64. Latin America Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 65. Latin America Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa Live Attenuated Vaccine Sales by Country (2015-2020) (K MT)
Table 67. Middle East and Africa Live Attenuated Vaccine Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa Live Attenuated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa Live Attenuated Vaccine Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 71. Middle East and Africa Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 73. Middle East and Africa Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Table 74. Astellas Pharma (Japan) Corporation Information
Table 75. Astellas Pharma (Japan) Description and Major Businesses
Table 76. Astellas Pharma (Japan) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. Astellas Pharma (Japan) Product
Table 78. Astellas Pharma (Japan) Recent Development
Table 79. CSL Limited (Australia) Corporation Information
Table 80. CSL Limited (Australia) Description and Major Businesses
Table 81. CSL Limited (Australia) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. CSL Limited (Australia) Product
Table 83. CSL Limited (Australia) Recent Development
Table 84. Emergent BioSolutions (U.S.) Corporation Information
Table 85. Emergent BioSolutions (U.S.) Description and Major Businesses
Table 86. Emergent BioSolutions (U.S.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Emergent BioSolutions (U.S.) Product
Table 88. Emergent BioSolutions (U.S.) Recent Development
Table 89. GlaxoSmithKline (U.K.) Corporation Information
Table 90. GlaxoSmithKline (U.K.) Description and Major Businesses
Table 91. GlaxoSmithKline (U.K.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. GlaxoSmithKline (U.K.) Product
Table 93. GlaxoSmithKline (U.K.) Recent Development
Table 94. Johnson & Johnson (U.S.) Corporation Information
Table 95. Johnson & Johnson (U.S.) Description and Major Businesses
Table 96. Johnson & Johnson (U.S.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. Johnson & Johnson (U.S.) Product
Table 98. Johnson & Johnson (U.S.) Recent Development
Table 99. MedImmune (U.S.) Corporation Information
Table 100. MedImmune (U.S.) Description and Major Businesses
Table 101. MedImmune (U.S.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 102. MedImmune (U.S.) Product
Table 103. MedImmune (U.S.) Recent Development
Table 104. Merck & Co (U.S.) Corporation Information
Table 105. Merck & Co (U.S.) Description and Major Businesses
Table 106. Merck & Co (U.S.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 107. Merck & Co (U.S.) Product
Table 108. Merck & Co (U.S.) Recent Development
Table 109. Pfizer (U.S.) Corporation Information
Table 110. Pfizer (U.S.) Description and Major Businesses
Table 111. Pfizer (U.S.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 112. Pfizer (U.S.) Product
Table 113. Pfizer (U.S.) Recent Development
Table 114. Sanofi Pasteur (France) Corporation Information
Table 115. Sanofi Pasteur (France) Description and Major Businesses
Table 116. Sanofi Pasteur (France) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Sanofi Pasteur (France) Product
Table 118. Sanofi Pasteur (France) Recent Development
Table 119. Serum Institute of India Pvt (India) Corporation Information
Table 120. Serum Institute of India Pvt (India) Description and Major Businesses
Table 121. Serum Institute of India Pvt (India) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 122. Serum Institute of India Pvt (India) Product
Table 123. Serum Institute of India Pvt (India) Recent Development
Table 124. Global Live Attenuated Vaccine Sales Forecast by Regions (2021-2026) (K MT)
Table 125. Global Live Attenuated Vaccine Sales Market Share Forecast by Regions (2021-2026)
Table 126. Global Live Attenuated Vaccine Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 127. Global Live Attenuated Vaccine Revenue Market Share Forecast by Regions (2021-2026)
Table 128. North America: Live Attenuated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 129. North America: Live Attenuated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 130. Europe: Live Attenuated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 131. Europe: Live Attenuated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 132. Asia Pacific: Live Attenuated Vaccine Sales Forecast by Region (2021-2026) (K MT)
Table 133. Asia Pacific: Live Attenuated Vaccine Revenue Forecast by Region (2021-2026) (US$ Million)
Table 134. Latin America: Live Attenuated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 135. Latin America: Live Attenuated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 136. Middle East and Africa: Live Attenuated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 137. Middle East and Africa: Live Attenuated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 138. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 139. Key Challenges
Table 140. Market Risks
Table 141. Main Points Interviewed from Key Live Attenuated Vaccine Players
Table 142. Live Attenuated Vaccine Customers List
Table 143. Live Attenuated Vaccine Distributors List
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
Table 1. Live Attenuated Vaccine Market Segments
Table 2. Ranking of Global Top Live Attenuated Vaccine Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Live Attenuated Vaccine Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Children
Table 5. Major Manufacturers of Adult
Table 6. COVID-19 Impact Global Market: (Four Live Attenuated Vaccine Market Size Forecast Scenarios)
Table 7. Opportunities and Trends for Live Attenuated Vaccine Players in the COVID-19 Landscape
Table 8. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 9. Key Regions/Countries Measures against Covid-19 Impact
Table 10. Proposal for Live Attenuated Vaccine Players to Combat Covid-19 Impact
Table 11. Global Live Attenuated Vaccine Market Size Growth Rate by Application 2020-2026 (K MT)
Table 12. Global Live Attenuated Vaccine Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 13. Global Live Attenuated Vaccine Sales by Regions 2015-2020 (K MT)
Table 14. Global Live Attenuated Vaccine Sales Market Share by Regions (2015-2020)
Table 15. Global Live Attenuated Vaccine Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Live Attenuated Vaccine Sales by Manufacturers (2015-2020) (K MT)
Table 17. Global Live Attenuated Vaccine Sales Share by Manufacturers (2015-2020)
Table 18. Global Live Attenuated Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Live Attenuated Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Live Attenuated Vaccine as of 2019)
Table 20. Live Attenuated Vaccine Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Live Attenuated Vaccine Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Live Attenuated Vaccine Price (2015-2020) (USD/MT)
Table 23. Live Attenuated Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Live Attenuated Vaccine Product Type
Table 25. Date of International Manufacturers Enter into Live Attenuated Vaccine Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 28. Global Live Attenuated Vaccine Sales Share by Type (2015-2020)
Table 29. Global Live Attenuated Vaccine Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Live Attenuated Vaccine Revenue Share by Type (2015-2020)
Table 31. Live Attenuated Vaccine Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 32. Global Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 33. Global Live Attenuated Vaccine Sales Share by Application (2015-2020)
Table 34. North America Live Attenuated Vaccine Sales by Country (2015-2020) (K MT)
Table 35. North America Live Attenuated Vaccine Sales Market Share by Country (2015-2020)
Table 36. North America Live Attenuated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 37. North America Live Attenuated Vaccine Revenue Market Share by Country (2015-2020)
Table 38. North America Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 39. North America Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Table 40. North America Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 41. North America Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Table 42. Europe Live Attenuated Vaccine Sales by Country (2015-2020) (K MT)
Table 43. Europe Live Attenuated Vaccine Sales Market Share by Country (2015-2020)
Table 44. Europe Live Attenuated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe Live Attenuated Vaccine Revenue Market Share by Country (2015-2020)
Table 46. Europe Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 47. Europe Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Table 48. Europe Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 49. Europe Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific Live Attenuated Vaccine Sales by Region (2015-2020) (K MT)
Table 51. Asia Pacific Live Attenuated Vaccine Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific Live Attenuated Vaccine Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific Live Attenuated Vaccine Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 55. Asia Pacific Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 57. Asia Pacific Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Table 58. Latin America Live Attenuated Vaccine Sales by Country (2015-2020) (K MT)
Table 59. Latin America Live Attenuated Vaccine Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa Live Attenuated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America Live Attenuated Vaccine Revenue Market Share by Country (2015-2020)
Table 62. Latin America Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 63. Latin America Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Table 64. Latin America Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 65. Latin America Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa Live Attenuated Vaccine Sales by Country (2015-2020) (K MT)
Table 67. Middle East and Africa Live Attenuated Vaccine Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa Live Attenuated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa Live Attenuated Vaccine Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa Live Attenuated Vaccine Sales by Type (2015-2020) (K MT)
Table 71. Middle East and Africa Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa Live Attenuated Vaccine Sales by Application (2015-2020) (K MT)
Table 73. Middle East and Africa Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Table 74. Astellas Pharma (Japan) Corporation Information
Table 75. Astellas Pharma (Japan) Description and Major Businesses
Table 76. Astellas Pharma (Japan) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. Astellas Pharma (Japan) Product
Table 78. Astellas Pharma (Japan) Recent Development
Table 79. CSL Limited (Australia) Corporation Information
Table 80. CSL Limited (Australia) Description and Major Businesses
Table 81. CSL Limited (Australia) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. CSL Limited (Australia) Product
Table 83. CSL Limited (Australia) Recent Development
Table 84. Emergent BioSolutions (U.S.) Corporation Information
Table 85. Emergent BioSolutions (U.S.) Description and Major Businesses
Table 86. Emergent BioSolutions (U.S.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Emergent BioSolutions (U.S.) Product
Table 88. Emergent BioSolutions (U.S.) Recent Development
Table 89. GlaxoSmithKline (U.K.) Corporation Information
Table 90. GlaxoSmithKline (U.K.) Description and Major Businesses
Table 91. GlaxoSmithKline (U.K.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. GlaxoSmithKline (U.K.) Product
Table 93. GlaxoSmithKline (U.K.) Recent Development
Table 94. Johnson & Johnson (U.S.) Corporation Information
Table 95. Johnson & Johnson (U.S.) Description and Major Businesses
Table 96. Johnson & Johnson (U.S.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. Johnson & Johnson (U.S.) Product
Table 98. Johnson & Johnson (U.S.) Recent Development
Table 99. MedImmune (U.S.) Corporation Information
Table 100. MedImmune (U.S.) Description and Major Businesses
Table 101. MedImmune (U.S.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 102. MedImmune (U.S.) Product
Table 103. MedImmune (U.S.) Recent Development
Table 104. Merck & Co (U.S.) Corporation Information
Table 105. Merck & Co (U.S.) Description and Major Businesses
Table 106. Merck & Co (U.S.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 107. Merck & Co (U.S.) Product
Table 108. Merck & Co (U.S.) Recent Development
Table 109. Pfizer (U.S.) Corporation Information
Table 110. Pfizer (U.S.) Description and Major Businesses
Table 111. Pfizer (U.S.) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 112. Pfizer (U.S.) Product
Table 113. Pfizer (U.S.) Recent Development
Table 114. Sanofi Pasteur (France) Corporation Information
Table 115. Sanofi Pasteur (France) Description and Major Businesses
Table 116. Sanofi Pasteur (France) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Sanofi Pasteur (France) Product
Table 118. Sanofi Pasteur (France) Recent Development
Table 119. Serum Institute of India Pvt (India) Corporation Information
Table 120. Serum Institute of India Pvt (India) Description and Major Businesses
Table 121. Serum Institute of India Pvt (India) Live Attenuated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 122. Serum Institute of India Pvt (India) Product
Table 123. Serum Institute of India Pvt (India) Recent Development
Table 124. Global Live Attenuated Vaccine Sales Forecast by Regions (2021-2026) (K MT)
Table 125. Global Live Attenuated Vaccine Sales Market Share Forecast by Regions (2021-2026)
Table 126. Global Live Attenuated Vaccine Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 127. Global Live Attenuated Vaccine Revenue Market Share Forecast by Regions (2021-2026)
Table 128. North America: Live Attenuated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 129. North America: Live Attenuated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 130. Europe: Live Attenuated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 131. Europe: Live Attenuated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 132. Asia Pacific: Live Attenuated Vaccine Sales Forecast by Region (2021-2026) (K MT)
Table 133. Asia Pacific: Live Attenuated Vaccine Revenue Forecast by Region (2021-2026) (US$ Million)
Table 134. Latin America: Live Attenuated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 135. Latin America: Live Attenuated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 136. Middle East and Africa: Live Attenuated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 137. Middle East and Africa: Live Attenuated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 138. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 139. Key Challenges
Table 140. Market Risks
Table 141. Main Points Interviewed from Key Live Attenuated Vaccine Players
Table 142. Live Attenuated Vaccine Customers List
Table 143. Live Attenuated Vaccine Distributors List
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Live Attenuated Vaccine Product Picture
Figure 2. Global Live Attenuated Vaccine Sales Market Share by Type in 2020 & 2026
Figure 3. Children Product Picture
Figure 4. Adult Product Picture
Figure 5. Global Live Attenuated Vaccine Sales Market Share by Application in 2020 & 2026
Figure 6. Hospital
Figure 7. Medical Center
Figure 8. Others
Figure 9. Live Attenuated Vaccine Report Years Considered
Figure 10. Global Live Attenuated Vaccine Market Size 2015-2026 (US$ Million)
Figure 11. Global Live Attenuated Vaccine Sales 2015-2026 (K MT)
Figure 12. Global Live Attenuated Vaccine Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Global Live Attenuated Vaccine Sales Market Share by Region (2015-2020)
Figure 14. Global Live Attenuated Vaccine Sales Market Share by Region in 2019
Figure 15. Global Live Attenuated Vaccine Revenue Market Share by Region (2015-2020)
Figure 16. Global Live Attenuated Vaccine Revenue Market Share by Region in 2019
Figure 17. Global Live Attenuated Vaccine Sales Share by Manufacturer in 2019
Figure 18. The Top 10 and 5 Players Market Share by Live Attenuated Vaccine Revenue in 2019
Figure 19. Live Attenuated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Figure 21. Global Live Attenuated Vaccine Sales Market Share by Type in 2019
Figure 22. Global Live Attenuated Vaccine Revenue Market Share by Type (2015-2020)
Figure 23. Global Live Attenuated Vaccine Revenue Market Share by Type in 2019
Figure 24. Global Live Attenuated Vaccine Market Share by Price Range (2015-2020)
Figure 25. Global Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Figure 26. Global Live Attenuated Vaccine Sales Market Share by Application in 2019
Figure 27. Global Live Attenuated Vaccine Revenue Market Share by Application (2015-2020)
Figure 28. Global Live Attenuated Vaccine Revenue Market Share by Application in 2019
Figure 29. North America Live Attenuated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 30. North America Live Attenuated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 31. North America Live Attenuated Vaccine Sales Market Share by Country in 2019
Figure 32. North America Live Attenuated Vaccine Revenue Market Share by Country in 2019
Figure 33. U.S. Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 34. U.S. Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. Canada Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 36. Canada Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. North America Live Attenuated Vaccine Market Share by Type in 2019
Figure 38. North America Live Attenuated Vaccine Market Share by Application in 2019
Figure 39. Europe Live Attenuated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 40. Europe Live Attenuated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 41. Europe Live Attenuated Vaccine Sales Market Share by Country in 2019
Figure 42. Europe Live Attenuated Vaccine Revenue Market Share by Country in 2019
Figure 43. Germany Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 44. Germany Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. France Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 46. France Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. U.K. Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 48. U.K. Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Italy Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 50. Italy Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Russia Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 52. Russia Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Europe Live Attenuated Vaccine Market Share by Type in 2019
Figure 54. Europe Live Attenuated Vaccine Market Share by Application in 2019
Figure 55. Asia Pacific Live Attenuated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 56. Asia Pacific Live Attenuated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 57. Asia Pacific Live Attenuated Vaccine Sales Market Share by Region in 2019
Figure 58. Asia Pacific Live Attenuated Vaccine Revenue Market Share by Region in 2019
Figure 59. China Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 60. China Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Japan Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 62. Japan Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. South Korea Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 64. South Korea Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. India Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 66. India Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Australia Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 68. Australia Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Taiwan Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 70. Taiwan Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Indonesia Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 72. Indonesia Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Thailand Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 74. Thailand Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Malaysia Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 76. Malaysia Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Philippines Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 78. Philippines Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Vietnam Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 80. Vietnam Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Asia Pacific Live Attenuated Vaccine Market Share by Type in 2019
Figure 82. Asia Pacific Live Attenuated Vaccine Market Share by Application in 2019
Figure 83. Latin America Live Attenuated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 84. Latin America Live Attenuated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 85. Latin America Live Attenuated Vaccine Sales Market Share by Country in 2019
Figure 86. Latin America Live Attenuated Vaccine Revenue Market Share by Country in 2019
Figure 87. Mexico Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 88. Mexico Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Brazil Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 90. Brazil Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Argentina Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 92. Argentina Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Latin America Live Attenuated Vaccine Market Share by Type in 2019
Figure 94. Latin America Live Attenuated Vaccine Market Share by Application in 2019
Figure 95. Middle East and Africa Live Attenuated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 96. Middle East and Africa Live Attenuated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 97. Middle East and Africa Live Attenuated Vaccine Sales Market Share by Country in 2019
Figure 98. Middle East and Africa Live Attenuated Vaccine Revenue Market Share by Country in 2019
Figure 99. Turkey Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 100. Turkey Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Saudi Arabia Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 102. Saudi Arabia Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. U.A.E Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 104. U.A.E Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Middle East and Africa Live Attenuated Vaccine Market Share by Type in 2019
Figure 106. Middle East and Africa Live Attenuated Vaccine Market Share by Application in 2019
Figure 107. Astellas Pharma (Japan) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 108. CSL Limited (Australia) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 109. Emergent BioSolutions (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. GlaxoSmithKline (U.K.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. Johnson & Johnson (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. MedImmune (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Merck & Co (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Pfizer (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Sanofi Pasteur (France) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Serum Institute of India Pvt (India) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. North America Live Attenuated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 118. North America Live Attenuated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Europe Live Attenuated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 120. Europe Live Attenuated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Asia Pacific Live Attenuated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 122. Asia Pacific Live Attenuated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Latin America Live Attenuated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 124. Latin America Live Attenuated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Middle East and Africa Live Attenuated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 126. Middle East and Africa Live Attenuated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 127. Porter's Five Forces Analysis
Figure 128. Channels of Distribution
Figure 129. Distributors Profiles
Figure 130. Bottom-up and Top-down Approaches for This Report
Figure 131. Data Triangulation
Figure 132. Key Executives Interviewed
Figure 1. Live Attenuated Vaccine Product Picture
Figure 2. Global Live Attenuated Vaccine Sales Market Share by Type in 2020 & 2026
Figure 3. Children Product Picture
Figure 4. Adult Product Picture
Figure 5. Global Live Attenuated Vaccine Sales Market Share by Application in 2020 & 2026
Figure 6. Hospital
Figure 7. Medical Center
Figure 8. Others
Figure 9. Live Attenuated Vaccine Report Years Considered
Figure 10. Global Live Attenuated Vaccine Market Size 2015-2026 (US$ Million)
Figure 11. Global Live Attenuated Vaccine Sales 2015-2026 (K MT)
Figure 12. Global Live Attenuated Vaccine Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Global Live Attenuated Vaccine Sales Market Share by Region (2015-2020)
Figure 14. Global Live Attenuated Vaccine Sales Market Share by Region in 2019
Figure 15. Global Live Attenuated Vaccine Revenue Market Share by Region (2015-2020)
Figure 16. Global Live Attenuated Vaccine Revenue Market Share by Region in 2019
Figure 17. Global Live Attenuated Vaccine Sales Share by Manufacturer in 2019
Figure 18. The Top 10 and 5 Players Market Share by Live Attenuated Vaccine Revenue in 2019
Figure 19. Live Attenuated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Live Attenuated Vaccine Sales Market Share by Type (2015-2020)
Figure 21. Global Live Attenuated Vaccine Sales Market Share by Type in 2019
Figure 22. Global Live Attenuated Vaccine Revenue Market Share by Type (2015-2020)
Figure 23. Global Live Attenuated Vaccine Revenue Market Share by Type in 2019
Figure 24. Global Live Attenuated Vaccine Market Share by Price Range (2015-2020)
Figure 25. Global Live Attenuated Vaccine Sales Market Share by Application (2015-2020)
Figure 26. Global Live Attenuated Vaccine Sales Market Share by Application in 2019
Figure 27. Global Live Attenuated Vaccine Revenue Market Share by Application (2015-2020)
Figure 28. Global Live Attenuated Vaccine Revenue Market Share by Application in 2019
Figure 29. North America Live Attenuated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 30. North America Live Attenuated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 31. North America Live Attenuated Vaccine Sales Market Share by Country in 2019
Figure 32. North America Live Attenuated Vaccine Revenue Market Share by Country in 2019
Figure 33. U.S. Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 34. U.S. Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. Canada Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 36. Canada Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. North America Live Attenuated Vaccine Market Share by Type in 2019
Figure 38. North America Live Attenuated Vaccine Market Share by Application in 2019
Figure 39. Europe Live Attenuated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 40. Europe Live Attenuated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 41. Europe Live Attenuated Vaccine Sales Market Share by Country in 2019
Figure 42. Europe Live Attenuated Vaccine Revenue Market Share by Country in 2019
Figure 43. Germany Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 44. Germany Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. France Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 46. France Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. U.K. Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 48. U.K. Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Italy Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 50. Italy Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Russia Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 52. Russia Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Europe Live Attenuated Vaccine Market Share by Type in 2019
Figure 54. Europe Live Attenuated Vaccine Market Share by Application in 2019
Figure 55. Asia Pacific Live Attenuated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 56. Asia Pacific Live Attenuated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 57. Asia Pacific Live Attenuated Vaccine Sales Market Share by Region in 2019
Figure 58. Asia Pacific Live Attenuated Vaccine Revenue Market Share by Region in 2019
Figure 59. China Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 60. China Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Japan Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 62. Japan Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. South Korea Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 64. South Korea Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. India Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 66. India Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Australia Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 68. Australia Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Taiwan Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 70. Taiwan Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Indonesia Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 72. Indonesia Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Thailand Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 74. Thailand Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Malaysia Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 76. Malaysia Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Philippines Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 78. Philippines Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Vietnam Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 80. Vietnam Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Asia Pacific Live Attenuated Vaccine Market Share by Type in 2019
Figure 82. Asia Pacific Live Attenuated Vaccine Market Share by Application in 2019
Figure 83. Latin America Live Attenuated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 84. Latin America Live Attenuated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 85. Latin America Live Attenuated Vaccine Sales Market Share by Country in 2019
Figure 86. Latin America Live Attenuated Vaccine Revenue Market Share by Country in 2019
Figure 87. Mexico Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 88. Mexico Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Brazil Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 90. Brazil Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Argentina Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 92. Argentina Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Latin America Live Attenuated Vaccine Market Share by Type in 2019
Figure 94. Latin America Live Attenuated Vaccine Market Share by Application in 2019
Figure 95. Middle East and Africa Live Attenuated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 96. Middle East and Africa Live Attenuated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 97. Middle East and Africa Live Attenuated Vaccine Sales Market Share by Country in 2019
Figure 98. Middle East and Africa Live Attenuated Vaccine Revenue Market Share by Country in 2019
Figure 99. Turkey Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 100. Turkey Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Saudi Arabia Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 102. Saudi Arabia Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. U.A.E Live Attenuated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 104. U.A.E Live Attenuated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Middle East and Africa Live Attenuated Vaccine Market Share by Type in 2019
Figure 106. Middle East and Africa Live Attenuated Vaccine Market Share by Application in 2019
Figure 107. Astellas Pharma (Japan) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 108. CSL Limited (Australia) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 109. Emergent BioSolutions (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. GlaxoSmithKline (U.K.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. Johnson & Johnson (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. MedImmune (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Merck & Co (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Pfizer (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Sanofi Pasteur (France) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Serum Institute of India Pvt (India) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. North America Live Attenuated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 118. North America Live Attenuated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Europe Live Attenuated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 120. Europe Live Attenuated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Asia Pacific Live Attenuated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 122. Asia Pacific Live Attenuated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Latin America Live Attenuated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 124. Latin America Live Attenuated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Middle East and Africa Live Attenuated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 126. Middle East and Africa Live Attenuated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 127. Porter's Five Forces Analysis
Figure 128. Channels of Distribution
Figure 129. Distributors Profiles
Figure 130. Bottom-up and Top-down Approaches for This Report
Figure 131. Data Triangulation
Figure 132. Key Executives Interviewed
